Researchers have reported promising results from a Phase II clinical trial evaluating sacituzumab govitecan in patients with advanced uterine cancer. The study enrolled 50 women whose disease had continued to progress despite standard treatments. Results showed that 70% of participants experienced tumor shrinkage, and 28% achieved a substantial reduction of at least 30%. These outcomes are considerably better than those typically seen with available third-line therapies.
Sacituzumab govitecan is an antibody-drug conjugate that targets Trop-2, a protein frequently found on uterine cancer cells. By delivering chemotherapy directly to cancer cells, the treatment aims to improve effectiveness while reducing damage to healthy tissue. The most common side effects involved bone marrow suppression and gastrointestinal symptoms, but overall the treatment was considered manageable and less toxic than conventional chemotherapy.
The findings provide hope for patients with treatment-resistant uterine cancer, a disease with limited therapeutic options. A larger Phase III trial is currently underway to determine whether the drug can improve outcomes compared with standard chemotherapy.